Abstract
A small number of studies were done on Hepatitis C virus genotypes 4, 5, and 6; that is why limited data were available on the most effective management for these patients. In the past, treatment of this kind of patients depended on the use of the suboptimal regimen of interferon with ribavirin achieving moderate efficacy with numerous side effects. However, with the introduction of the new directly acting antiviral drugs (DAAs), multiple agents became available for treatment showing high success rates, excellent tolerability, and few adverse events.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
